Like ATM, CHEK2 is not on the ACMG3.2 gene list of recommendations for reporting incidental findings [33], but discussions related to the inclusion of further moderate penetrance breast cancer genes, including both ATM and CHEK2, are ongoing [39]; both of the above variants are tested clinically in the UK, according to set guidelines [40]. This evidence concerns the gene ATM and breast cancer.